NCT07218146 2026-03-13
DLLEVATE
Zai Lab (Hong Kong), Ltd.
Phase 3 Recruiting
Clinical Trials
17 trialsNCT07010263 2026-03-05
AK112-311
Akeso
Phase 3 Recruiting
NCT06646276 2026-03-04
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT06992609 2026-03-02
ALBORAN
AstraZeneca
Phase 3 Recruiting
NCT06117774 2026-02-27
DeLLphi-306
Amgen
Phase 3 Recruiting
NCT07005128 2026-02-27
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT06712355 2026-02-13
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT07189455 2026-01-05
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Recruiting
NCT06457906 2025-07-16
SHARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04155034 2025-05-25
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06498479 2024-10-16
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT06095583 2024-06-21
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06128837 2024-03-15
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06247605 2024-02-08
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Advenchen Laboratories, LLC
Phase 3 Recruiting